• 1
    Warnakulasuriya KA, Johnson NW, Van Der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med 2007; in press.
  • 2
    Napier SS, Speight PM. Natural history of potentially malignant disorders: an overview of the literature. J Oral Pathol Med 2007; in press.
  • 3
    Scheifele C, Reichart PA. Is there a natural limit of the transformation rate of oral leukoplakia? Oral Oncol 2003; 39: 4705.
  • 4
    MacDonald DG, Reibel J, Bouquot J, Warnakulasuriya KA, Dabelsteen E. Oral epithelial dysplasia classification systems: predictive value; utility, weaknesses and scope for improvement. J Oral Pathol Med 2007; in press.
  • 5
    Zhang L, Rosin MP. Loss of heterozygosity: a potential tool in management of oral premalignant lesions? J Oral Pathol Med 2001; 30: 51320.
  • 6
    Marley JJ, Cowan CG, Lamey PJ, Linden GJ, Johnson NW, Warnakulasuriya KA. Management of potentially malignant oral mucosal lesions by consultant UK oral and maxillofacial surgeons. Br J Oral Maxillofac Surg 1996; 34: 2836.
  • 7
    Marley JJ, Linden GJ, Cowan CG, et al. A comparison of the management of potentially malignant oral mucosal lesions by oral medicine practitioners and oral & maxillofacial surgeons in the UK. J Oral Pathol Med 1998; 27: 48995.
  • 8
    Schwarz F, Maraki D, Yalcinkaya S, Bieling K, Bocking A, Becker J. Cytologic and DNA-cytometric follow-up of oral leukoplakia after CO2- and Er:YAG-laser assisted ablation: a pilot study. Lasers Surg Med 2005; 37: 2936.
  • 9
    Chandu A, Smith AC. The use of CO2 laser in the treatment of oral white patches: outcomes and factors affecting recurrence. Int J Oral Maxillofac Surg 2005; 34: 396400.
  • 10
    Chiesa F, Sala L, Costa L, et al. Excision of oral leukoplakias by CO2 laser on an out-patient basis: a useful procedure for prevention and early detection of oral carcinomas. Tumori 1986; 72: 30712.
  • 11
    Chu FW, Silverman S Jr, Dedo HH. CO2 laser treatment of oral leukoplakia. Laryngoscope 1988; 98: 12530.
  • 12
    Flynn MB, White M, Tabah RJ. Use of carbon dioxide laser for the treatment of premalignant lesions of the oral mucosa. J Surg Oncol 1988; 37: 2324.
  • 13
    Frame JW, Das Gupta AR, Dalton GA, Rhys Evans PH. Use of the carbon dioxide laser in the management of premalignant lesions of the oral mucosa. J Laryngol Otol 1984; 98: 125160.
  • 14
    Holmstrup P, Vedtofte P, Reibel J, Stoltze K. Long-term treatment outcome of oral premalignant lesions. Oral Oncol 2006; 42: 46174.
  • 15
    Ishii J, Fujita K, Munemoto S, Komori T. Management of oral leukoplakia by laser surgery: relation between recurrence and malignant transformation and clinicopathological features. J Clin Laser Med Surg 2004; 22: 2733.
  • 16
    Pandey M, Thomas G, Somanathan T, et al. Evaluation of surgical excision of non-homogeneous oral leukoplakia in a screening intervention trial, Kerala, India. Oral Oncol 2001; 37: 1039.
  • 17
    Roodenburg JL, Panders AK, Vermey A. Carbon dioxide laser surgery of oral leukoplakia. Oral Surg Oral Med Oral Pathol 1991; 71: 6704.
  • 18
    Saito T, Sugiura C, Hirai A, et al. Development of squamous cell carcinoma from pre-existent oral leukoplakia: with respect to treatment modality. Int J Oral Maxillofac Surg 2001; 30: 4953.
  • 19
    Sako K, Marchetta FC, Hayes RL. Cryotherapy of intraoral leukoplakia. Am J Surg 1972; 124: 4824.
  • 20
    Schoelch ML, Sekandari N, Regezi JA, Silverman S Jr. Laser management of oral leukoplakias: a follow-up study of 70 patients. Laryngoscope 1999; 109: 94953.
  • 21
    Thomson PJ, Wylie J. Interventional laser surgery: an effective surgical and diagnostic tool in oral precancer management. Int J Oral Maxillofac Surg 2002; 31: 14553.
  • 22
    Van Der Hem PS, Nauta JM, Van Der Wal JE, Roodenburg JL. The results of CO2 laser surgery in patients with oral leukoplakia: a 25 year follow up. Oral Oncol 2005; 41: 317.
  • 23
    Schepman KP, Van Der Meij EH, Smeele LE, Van Der Waal I. Malignant transformation of oral leukoplakia: a follow-up study of a hospital-based population of 166 patients with oral leukoplakia from The Netherlands. Oral Oncol 1998; 34: 2705.
  • 24
    Einhorn J, Wersall J. Incidence of oral carcinoma in patients with leukoplakia of the oral mucosa. Cancer 1967; 20: 218993.
  • 25
    Chiesa F, Tradati N, Sala L, et al. Follow-up of oral leukoplakia after carbon dioxide laser surgery. Arch Otolaryngol Head Neck Surg 1990; 116: 17780.
  • 26
    Ishii J, Fujita K, Komori T. Laser surgery as a treatment for oral leukoplakia. Oral Oncol 2003; 39: 75969.
  • 27
    Lodi G, Sardella A, Bez C, Demarosi F, Carrassi A. Interventions for treating oral leukoplakia. Cochrane Database Syst Rev 2006; CD001829.
  • 28
    Gaeta GM, Gombos F, Femiano F, et al. Acitretin and treatment of the oral leucoplakias: a model to have an active molecules release. J Eur Acad Dermatol Venereol 2000; 14: 4738.
  • 29
    Hong WK, Endicott J, Itri LM, et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986; 315: 15015.
  • 30
    Piattelli A, Fioroni M, Santinelli A, Rubini C. Bcl-2 expression and apoptotic bodies in 13-cis-retinoic acid (isotretinoin)-topically treated oral leukoplakia: a pilot study. Oral Oncol 1999; 35: 31420.
  • 31
    Sankaranarayanan R, Mathew B, Varghese C, et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncol 1997; 33: 2316.
  • 32
    Stich HF, Hornby AP, Mathew B, Sankaranarayanan R, Nair MK. Response of oral leukoplakias to the administration of vitamin A. Cancer Lett 1988; 40: 93101.
  • 33
    Singh M, Krishanappa R, Bagewadi A, Keluskar V. Efficacy of oral lycopene in the treatment of oral leukoplakia. Oral Oncol 2004; 40: 5916.
  • 34
    Mulshine JL, Atkinson JC, Greer RO, et al. Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res 2004; 10: 156573.
  • 35
    Epstein JB, Wong FL, Millner A, Le ND. Topical bleomycin treatment of oral leukoplakia: a randomized double-blind clinical trial. Head Neck 1994; 16: 53944.
  • 36
    Li N, Sun Z, Han C, Chen J. The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proc Soc Exp Biol Med 1999; 220: 21824.
  • 37
    Schepman KP, Bezemer PD, Van Der Meij EH, Smeele LE, Van Der Waal I. Tobacco usage in relation to the anatomical site of oral leukoplakia. Oral Dis 2001; 7: 257.
  • 38
    Gupta PC, Murti PR, Bhonsle RB, Mehta FS, Pindborg JJ. Effect of cessation of tobacco use on the incidence of oral mucosal lesions in a 10-year follow-up study of 12,212 users. Oral Dis 1995; 1: 548.
  • 39
    Roed-Petersen B. Effect on oral leukoplakia of reducing or ceasing tobacco smoking. Acta Derm Venereol 1982; 62: 1647.
  • 40
    Martin GC, Brown JP, Eifler CW, Houston GD. Oral leukoplakia status six weeks after cessation of smokeless tobacco use. J Am Dent Assoc 1999; 130: 94554.
  • 41
    Vedtofte P, Holmstrup P, Hjorting-Hansen E, Pindborg JJ. Surgical treatment of premalignant lesions of the oral mucosa. Int J Oral Maxillofac Surg 1987; 16: 65664.
  • 42
    Ribeiro NF, Godden DR, Wilson GE, Butterworth DM, Woodwards RT. Do frozen sections help achieve adequate surgical margins in the resection of oral carcinoma? Int J Oral Maxillofac Surg 2003; 32: 1528.
  • 43
    Weijers M, Snow GB, Bezemer DP, Van Der Waal JE, Van Der Waal I. The status of the deep surgical margins in tongue and floor of mouth squamous cell carcinoma and risk of local recurrence: an analysis of 68 patients. Int J Oral Maxillofac Surg 2004; 33: 1469.
  • 44
    Bekke JP, Baart JA. Six years’ experience with cryosurgery in the oral cavity. Int J Oral Surg 1979; 8: 25170.
  • 45
    Gongloff RK, Gage AA. Cryosurgical treatment of oral lesions: report of cases. J Am Dent Assoc 1983; 106: 4751.
  • 46
    Gluckman JL. Hematoporphyrin photodynamic therapy: is there truly a future in head and neck oncology? Reflections on a 5-year experience. Laryngoscope 1991; 101: 3642.
  • 47
    Fan KF, Hopper C, Speight PM, Buonaccorsi G, MacRobert AJ, Bown SG. Photodynamic therapy using 5-aminolevulinic acid for premalignant and malignant lesions of the oral cavity. Cancer 1996; 78: 137483.
  • 48
    Hopper C, Niziol C, Sidhu M. The cost-effectiveness of Foscan mediated photodynamic therapy (Foscan-PDT) compared with extensive palliative surgery and palliative chemotherapy for patients with advanced head and neck cancer in the UK. Oral Oncol 2004; 40: 37282.
  • 49
    Tsai JC, Chiang CP, Chen HM, et al. Photodynamic therapy of oral dysplasia with topical 5-aminolevulinic acid and light-emitting diode array. Lasers Surg Med 2004; 34: 1824.
  • 50
    Lou PJ, Jager HR, Jones L, Theodossy T, Bown SG, Hopper C. Interstitial photodynamic therapy as salvage treatment for recurrent head and neck cancer. Br J Cancer 2004; 91: 4416.
  • 51
    Holsinger FC, Doan DD, Jasser SA, et al. Epidermal growth factor receptor blockade potentiates apoptosis mediated by paclitaxel and leads to prolonged survival in a murine model of oral cancer. Clin Cancer Res 2003; 9: 31839.
  • 52
    Ha PK, Califano JA. The role of human papillomavirus in oral carcinogenesis. Crit Rev Oral Biol Med 2004; 15: 18896.
  • 53
    Syrjanen S. Human papillomavirus (HPV) in head and neck cancer. J Clin Virol 2005; 32(Suppl. 1): 5966.
  • 54
    Szentirmay Z, Polus K, Tamas L, et al. Human papillomavirus in head and neck cancer: molecular biology and clinicopathological correlations. Cancer Metastasis Rev 2005; 24: 1934.
  • 55
    Majewski S, Jablonska S. New treatments for cutaneous human papillomavirus infection. J Eur Acad Dermatol Venereol 2004; 18: 2624.
  • 56
    Hagensee ME. Infection with human papillomavirus: update on epidemiology, diagnosis, and treatment. Curr Infect Dis Rep 2000; 2: 1824.
  • 57
    Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 175765.
  • 58
    Roden RB, Ling M, Wu TC. Vaccination to prevent and treat cervical cancer. Hum Pathol 2004; 35: 97182.
  • 59
    Renstrup G. Occurrence of candida in oral leukoplakias. Acta Pathol Microbiol Scand [B] Microbiol Immunol 1970; 78: 4214.
  • 60
    Barrett AW, Kingsmill VJ, Speight PM. The frequency of fungal infection in biopsies of oral mucosal lesions. Oral Dis 1998; 4: 2631.
  • 61
    McCullough M, Jaber M, Barrett AW, Bain L, Speight PM, Porter SR. Oral yeast carriage correlates with presence of oral epithelial dysplasia. Oral Oncol 2002; 38: 3913.
  • 62
    Franklin CD, Martin MV. The effects of Candida albicans on turpentine-induced hyperplasia of hamster cheek pouch epithelium. J Med Vet Mycol 1986; 24: 2817.
  • 63
    Sitheeque MA, Samaranayake LP. Chronic hyperplastic candidosis/candidiasis (candidal leukoplakia). Crit Rev Oral Biol Med 2003; 14: 25367.
  • 64
    Cawson RA, Lehner T. Chronic hyperplastic candidiasis-candidal leukoplakia. Br J Dermatol 1968; 80: 916.
  • 65
    Lamey PJ, Lewis MA, MacDonald DG. Treatment of candidal leukoplakia with fluconazole. Br Dent J 1989; 166: 2968.
  • 66
    Jaber MA, Porter SR, Gilthorpe MS, Bedi R, Scully C. Risk factors for oral epithelial dysplasia: the role of smoking and alcohol. Oral Oncol 1999; 35: 1516.
  • 67
    Morse DE, Pendrys DG, Katz RV, et al. Food group intake and the risk of oral epithelial dysplasia in a United States population. Cancer Causes Control 2000; 11: 71320.